Redcare Pharmacy Shares Surge on Stellar Quarterly Performance

European online pharmacy leader Redcare Pharmacy witnessed an extraordinary market response as its stock price skyrocketed by up to 19 percent following the release of third-quarter results that surpassed even the most optimistic market expectations. The dramatic investor confidence boost stems from several key performance indicators that indicate robust operational momentum.

International Expansion Gains Traction

The company’s strategic international push is yielding significant returns, with revenue across Belgium, Italy, France, and the Netherlands climbing 25.4 percent to reach €132 million. Customer engagement continues to strengthen, with the platform now serving 13.7 million active customers—representing an increase of 200,000 from the previous quarter.

Beyond geographical diversification, Redcare demonstrated balanced growth across its business segments. Total revenue advanced 25.2 percent to €719 million, supported by solid performance in all operational areas. Even the non-prescription segment, encompassing over-the-counter products, registered nearly 17 percent growth.

Prescription Business Delivers Breakthrough Performance

The most striking development emerged from Redcare’s German prescription medication division, which delivered what market observers are calling a transformational performance. After two quarters of modest results, prescription drug revenue catapulted 82 percent to €126 million, matching even the most ambitious analyst projections.

Should investors sell immediately? Or is it worth buying Redcare Pharmacy NV?

The sequential quarterly improvement tells an equally compelling story. Growth accelerated to €12 million from the meager €6 million increase recorded in the second quarter, signaling renewed momentum. Chief Executive Officer Olaf Heinrich characterized this as “strong Q3 dynamics” while reaffirming full-year guidance.

Looking at the broader picture, German prescription sales through the first nine months of 2025 have exploded 122 percent to €348 million, highlighting the accelerating digital transformation within the pharmaceutical sector.

Analyst Perspective and Future Catalysts

Investment firm Jefferies attributes this success to targeted marketing initiatives, particularly highlighting the “direct eRx bonus campaign following the summer period.” Market researchers identify multiple potential growth drivers on the horizon, including repeat prescriptions, modifications in chronic disease treatments, and expanding brand recognition among German consumers.

Despite upcoming leadership changes—Chief Financial Officer Jasper Eenhorst is departing—Redcare maintained all annual targets. The company continues to project revenue growth exceeding 25 percent alongside an EBITDA margin between 2 and 2.5 percent. Achieving at least €500 million in prescription revenue appears increasingly attainable given current trajectory.